FDA, EMA, PMDA, Health Canada, and WHO update their guidance constantly. Some changes take effect immediately, others come with transition periods, and every region has its own formats and expectations.
Most regulatory teams still keep up the hard way: scanning health authority websites, reading newsletters, interpreting long guidance documents, and manually figuring out which SOPs, protocols, and templates need to change. It eats hundreds of hours a month, it's easy to miss something, and it leaves skilled people little time for strategy or engaging with regulators. A missed update can mean delayed launches, costly rework, fines, or worse.
| Number | What it means |
|---|---|
| 50–70% | Reduction in drafting time when teams start from compliant, AI-generated templates |
| 4 months | Time cut from NDA preparation for a mid-sized oncology pharma company |
| 70% | Reduction in regulatory monitoring costs for a rare disease biotech startup |
| 100% | EU portfolio compliance achieved in year one by a medical device manufacturer transitioning to MDR/IVDR |
| Weeks → days | Submission preparation time with automated drafting |
Regulatory complexity is growing faster than regulatory teams. Every new market, product, or guideline adds more to monitor and more documents to update. Generative AI has moved past the experimental stage, and early adopters are already shortening submission cycles and catching changes before deadlines. The longer teams rely on manual monitoring, the wider the gap gets, especially in competitive therapeutic areas where a few weeks can decide who reaches market first.
Turn regulatory change into a head start, not a fire drill. See the capabilities, roadmap, and ROI measures in full.